1. 363 An ongoing Phase 1 dose-escalation study of the folic acid-tubulysin small-molecule drug conjugate (SMDC) folate-tubulysin EC1456. (September 2015) Authors: Edelman, M.; Matei, D.; Harb, W.; Clark, R.; Sachdev, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 338 Results from a phase 1 study of ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma. (September 2015) Authors: Tolcher, A.; Harb, W.; Sachdev, J.; Papadopoulos, K.; Bordoni, R.; Chai, F.; Larmar, M.; Savage, R.; Abbadessa, G.; Saleh, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy. (1st April 2022) Authors: Fenstermacher, M. E.; Abbate, J.; Abe, S.; Abrams, T.; Adams, M.; Adamson, B.; Aiba, N.; Akiyama, T.; Aleynikov, P.; Allen, E.; Allen, S.; Anand, H.; Anderson, J.; Andrew, Y.; Andrews, T.; Appelt, D.; Arbon, R.; Ashikawa, N.; Ashourvan, A.; Aslin, M. Journal: Nuclear fusion Issue: Volume 62:Number 4(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗